File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The Value of Prognostic Nutritional Index in Follicular Lymphoma

TitleThe Value of Prognostic Nutritional Index in Follicular Lymphoma
Authors
Keywordsprognostic factor
survival
follicular lymphoma
serum albumin
lymphocyte
Issue Date2019
Citation
American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, v. 42, n. 2, p. 202-207 How to Cite?
AbstractObjectives: Previous studies reported that prognostic nutritional index (PNI), a marker of host inflammatory and nutritional status, is associated with prognoses in a number of cancer types. Thus, we investigated PNI at diagnosis as a prognostic factor in FL. Methods: We reviewed FL patients in Tuen Mun Hospital, Hong Kong from 2000 to 2014 (n=88). PNI was calculated by serum albumin (g/L)+5×absolute lymphocyte count (10 9 /L). We determined the best PNI cut-off value using receiver-operating characteristic curves. The extent to which progression-free survival (PFS) and overall survival differed by PNI cut-off was assessed using Kaplan-Meier and log-rank tests. Cox proportional hazards model was utilized to adjust for covariates. Results: The best cut-off value for PNI was determined to be 45. Patients with high PNI (>45) had a higher complete response (CR) rate after primary treatment, 46 of 61 (75.4%) patients with high PNI had CR, compared with 10 of 23 (43.5%) for low PNI (2-sample test of proportions P-value=0.006). Further, higher PNI at relapse as a continuous variable was associated with superior postprogression survival with a hazard ratio (HR) 0.88 (95% confidence interval [CI], 0.81-0.96). In multivariate analysis, high PNI at diagnosis had superior PFS (adjusted HR of 0.37; 95% CI, 0.15-0.93). Conclusions: PNI was shown to be independent prognostic factor of PFS in FL. It is a cheap and widely available biomarker. Future study is needed to validate its prognostic value and clinical utility in a prospective cohort.
Persistent Identifierhttp://hdl.handle.net/10722/303588
ISSN
2021 Impact Factor: 2.787
2020 SCImago Journal Rankings: 0.896
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLee, Shing Fung-
dc.contributor.authorNg, Ting Ying-
dc.contributor.authorWong, Frank Chi Sing-
dc.date.accessioned2021-09-15T08:25:37Z-
dc.date.available2021-09-15T08:25:37Z-
dc.date.issued2019-
dc.identifier.citationAmerican Journal of Clinical Oncology: Cancer Clinical Trials, 2019, v. 42, n. 2, p. 202-207-
dc.identifier.issn0277-3732-
dc.identifier.urihttp://hdl.handle.net/10722/303588-
dc.description.abstractObjectives: Previous studies reported that prognostic nutritional index (PNI), a marker of host inflammatory and nutritional status, is associated with prognoses in a number of cancer types. Thus, we investigated PNI at diagnosis as a prognostic factor in FL. Methods: We reviewed FL patients in Tuen Mun Hospital, Hong Kong from 2000 to 2014 (n=88). PNI was calculated by serum albumin (g/L)+5×absolute lymphocyte count (10 9 /L). We determined the best PNI cut-off value using receiver-operating characteristic curves. The extent to which progression-free survival (PFS) and overall survival differed by PNI cut-off was assessed using Kaplan-Meier and log-rank tests. Cox proportional hazards model was utilized to adjust for covariates. Results: The best cut-off value for PNI was determined to be 45. Patients with high PNI (>45) had a higher complete response (CR) rate after primary treatment, 46 of 61 (75.4%) patients with high PNI had CR, compared with 10 of 23 (43.5%) for low PNI (2-sample test of proportions P-value=0.006). Further, higher PNI at relapse as a continuous variable was associated with superior postprogression survival with a hazard ratio (HR) 0.88 (95% confidence interval [CI], 0.81-0.96). In multivariate analysis, high PNI at diagnosis had superior PFS (adjusted HR of 0.37; 95% CI, 0.15-0.93). Conclusions: PNI was shown to be independent prognostic factor of PFS in FL. It is a cheap and widely available biomarker. Future study is needed to validate its prognostic value and clinical utility in a prospective cohort.-
dc.languageeng-
dc.relation.ispartofAmerican Journal of Clinical Oncology: Cancer Clinical Trials-
dc.subjectprognostic factor-
dc.subjectsurvival-
dc.subjectfollicular lymphoma-
dc.subjectserum albumin-
dc.subjectlymphocyte-
dc.titleThe Value of Prognostic Nutritional Index in Follicular Lymphoma-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1097/COC.0000000000000493-
dc.identifier.pmid30499839-
dc.identifier.scopuseid_2-s2.0-85057731946-
dc.identifier.volume42-
dc.identifier.issue2-
dc.identifier.spage202-
dc.identifier.epage207-
dc.identifier.eissn1537-453X-
dc.identifier.isiWOS:000465420000016-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats